- Investing Ideas
- U.S. Pharmaceuticals & Biotech Leverage Leaders
U.S. Pharmaceuticals & Biotech Leverage Leaders
Results
87
87 companies
Denali Therapeutics
Market Cap: US$4.3b
A biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
DNLI
US$25.68
7D
-0.6%
1Y
76.9%
Praxis Precision Medicines
Market Cap: US$9.3b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$324.99
7D
2.0%
1Y
543.0%
Bio-Rad Laboratories
Market Cap: US$7.9b
Develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
BIO
US$296.11
7D
-0.3%
1Y
15.2%
Repligen
Market Cap: US$8.1b
A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
RGEN
US$144.24
7D
1.3%
1Y
10.8%
BeOne Medicines
Market Cap: US$33.7b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$298.70
7D
0.4%
1Y
19.3%
Monte Rosa Therapeutics
Market Cap: US$2.1b
A clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins.
GLUE
US$23.04
7D
-4.8%
1Y
346.5%
Cogent Biosciences
Market Cap: US$6.9b
A clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases.
COGT
US$38.87
7D
0.5%
1Y
254.0%
Mineralys Therapeutics
Market Cap: US$2.6b
A biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
MLYS
US$28.38
7D
2.5%
1Y
95.9%
Agios Pharmaceuticals
Market Cap: US$2.5b
A biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
AGIO
US$41.23
7D
9.7%
1Y
5.6%
Veradermics
Market Cap: US$5.2b
A clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions.
MANE
US$119.60
7D
-7.8%
1Y
n/a
Nuvalent
Market Cap: US$9.8b
A clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
NUVL
US$123.90
7D
0.1%
1Y
53.1%
Ocular Therapeutix
Market Cap: US$2.3b
A biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.
OCUL
US$10.20
7D
5.8%
1Y
-7.5%
Dyne Therapeutics
Market Cap: US$4.0b
A clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States.
DYN
US$23.42
7D
1.5%
1Y
171.1%
Crinetics Pharmaceuticals
Market Cap: US$8.8b
A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
CRNX
US$83.58
7D
97.9%
1Y
161.8%
Kardigan
Market Cap: US$2.2b
Operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases.
KARD
US$24.64
7D
1.2%
1Y
n/a